FDA to alter biosimilar ‘suffix’ policy

The US Food and Drug Administration (FDA) yesterday announced draft revisions to its policy on the naming of biosimilars, in an attempt to appease critics who say that renaming previously-licensed products is too expensive.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Careers

Squire Patton Boggs promotes partner to head Europe IP&T practice

1 May 2026 The IP expert will use his new role to support clients in cross-border challenges driven by innovation, digitalisation, market pressure and regulatory change.

Americas

From the courtroom: Hikma v Amarin SCOTUS oral arguments

30 April 2026 The Supreme Court's first look at the skinny label dispute dug into key questions, from the role of the skinny label to who Hikma’s statements were really meant for, in one of the most important patent cases in years.

Europe

Report: 85% of in-house counsel want IP service providers to embrace AI

30 April 2026 Data from Questel indicates a radical restructuring of IP professionals’ duties, as adoption and demand rates continue to rise.